Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity-Reference-Cited by-同舟云学术

Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity

Published:2020-09-03 Issue:12 Volume:28 Page:6145-6157
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Shannon Vickie R.,Anderson Ronald,Blidner Ada,Choi Jennifer,Cooksley Tim,Dougan Michael,Glezerman Ilya,Ginex Pamela,Girotra Monica,Gupta Dipti,Johnson Douglas B.,Suarez-Almazor Maria E.,Rapoport Bernardo L.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00520-020-05708-2.pdf

Reference79 articles.

1. Andruska N, Mahapatra L, Hebbard C, Patel P, Paul V (2018) Severe pneumonitis refractory to steroids following anti-PD-1 immunotherapy. BMJ Case Rep 2018:225937. https://doi.org/10.1136/bcr-2018-225937

2. Balaji A, Verde F, Suresh K, Naidoo J (2017) Pneumonitis from anti-PD-1/ PD-L1 therapy. Oncology (Williston Park) 31(10):739–746 754

3. Koyama N, Iwase O, Nakashima E, Kishida K, Kondo T, Watanabe Y, Takahashi H, Umebayashi Y, Ogawa Y, Miura H (2018) High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review. BMC Pulm Med 18:23. https://doi.org/10.1186/s12890-018-0592-x

4. Louvel G, Bahleda R, Ammari S, Le Pechoux C, Levy A, Massard C, Le Pavec J, Champiat S, Deutsch E (2018) Immunotherapy and pulmonary toxicities: can concomitant immune-checkpoint inhibitors with radiotherapy increase the risk of radiation pneumonitis? Eur Respir J 51(1):1701737. https://doi.org/10.1183/13993003.01737-2017

5. Ma K, Lu Y, Jiang S, Tang J, Li X, Zhang Y (2018) The relative risk and incidence of immune checkpoint inhibitors related pneumonitis in patients with advanced cancer: a meta-analysis. Front Pharmacol 9:1430. https://doi.org/10.3389/fphar.2018.01430

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An autopsy case of lung adenocarcinoma with immune checkpoint inhibitor-induced pneumonia and fulminant myocarditis following pembrolizumab administration: a case report;International Cancer Conference Journal;2024-03-30

2. Immune Checkpoint Inhibitors and Systemic Side Effects: Overview for the Inpatient Dermatologist;Current Dermatology Reports;2023-11-30

3. Six-week oral prednisolone therapy for immune-related pneumonitis: a single-arm phase II study;Journal for ImmunoTherapy of Cancer;2023-07

4. A case report and literature review of immune checkpoint inhibitor-associated pneumonia caused by penpulimab;Frontiers in Immunology;2023-06-22

5. Toxic and infectious lung injury differential diagnosis specifics in oncohematological patients;Oncohematology;2023-05-30